Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Ustekinumab associated with flares of psoriatic arthritis.

Stamell EF, Kutner A, Viola K, Cohen SR.

JAMA Dermatol. 2013 Dec;149(12):1410-3. doi: 10.1001/jamadermatol.2013.5728.

PMID:
24132520
2.

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.

de Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE.

Br J Dermatol. 2013 Jan;168(1):210-2. doi: 10.1111/j.1365-2133.2012.11206.x.

PMID:
23278559
3.

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

Croxtall JD.

Am J Clin Dermatol. 2012 Apr 1;13(2):135-7. doi: 10.2165/11208650-000000000-00000.

PMID:
22201419
4.

Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Croxtall JD.

Drugs. 2011 Sep 10;71(13):1733-53. doi: 10.2165/11207530-000000000-00000. Review.

PMID:
21902296
5.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

6.

Ustekinumab: a review of its use in psoriatic arthritis.

McKeage K.

Drugs. 2014 Jun;74(9):1029-39. doi: 10.1007/s40265-014-0242-4. Review.

PMID:
24919864
7.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
8.

Infliximab in psoriasis and psoriatic arthritis.

Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A.

BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. Review.

PMID:
23990278
9.

Ustekinumab.

Weber J, Keam SJ.

BioDrugs. 2009;23(1):53-61. doi: 10.2165/00063030-200923010-00006. Review.

PMID:
19344192
10.

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review.

11.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups.

Ann Rheum Dis. 2014 Jun;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741. Epub 2014 Feb 19.

12.

Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.

Zaghi D, Krueger GG, Callis Duffin K.

J Drugs Dermatol. 2012 Feb;11(2):160-7. Review.

PMID:
22270196
13.

Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.

Baerveldt EM, Onderdijk AJ, Kurek D, Kant M, Florencia EF, Ijpma AS, van der Spek PJ, Bastiaans J, Jansen PA, van Kilsdonk JW, Laman JD, Prens EP.

Br J Dermatol. 2013 May;168(5):990-8. doi: 10.1111/bjd.12175.

PMID:
23278632
14.

Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.

Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG.

J Drugs Dermatol. 2013 Oct;12(10):1098-102.

PMID:
24085044
15.

Ustekinumab for the treatment of psoriatic arthritis.

Wofford J, Menter A.

Expert Rev Clin Immunol. 2014 Feb;10(2):189-202. doi: 10.1586/1744666X.2014.878649. Review.

PMID:
24410536
16.

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).

Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B; LOTUS Investigators.

J Drugs Dermatol. 2013 Feb;12(2):166-74.

PMID:
23377389
17.

Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.

Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K.

Br J Dermatol. 2015 Jul;173(1):272-4. doi: 10.1111/bjd.13645. Epub 2015 May 18. No abstract available.

PMID:
25557081
18.

Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.

Gutiérrez-González E, Batalla A, de la Mano D.

Dermatol Online J. 2014 Apr 16;20(4):22338.

19.

Treatment of psoriasis and psoriatic arthritis.

Papoutsaki M, Costanzo A.

BioDrugs. 2013 Jan;27 Suppl 1:3-12. doi: 10.1007/BF03325637. Review.

PMID:
23990277
20.

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.

Kurzeja M, Rudnicka L, Olszewska M.

Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000. Review.

PMID:
21348542
Items per page

Supplemental Content

Write to the Help Desk